Mutant PDGF-B as a VEGFR inhibitor

Tech ID: T-018996

Technology Description

Researchers in the Imoukhuede lab at Washington University have developed a library of mutant PDGF-B proteins to develop more effective VEGF pathway inhibitors. As PDGF-B also binds to VEGF receptors, a mutant form can be used to block VEGF binding and stop tumor angiogenesis.

Bevacizumab, a successful VEGF inhibitor, is used in a variety of cancers to prevent angiogenesis. However, its efficacy is reduced due to the cross-family receptor binding of PDGF to VEGF receptors. Blocking VEGFR2 occupancy with mutant PDGF-B is a more effective strategy to prevent angiogenesis.

Stage of Research

The researchers have developed a PDGF-B mutagenesis library and are screening potential mutants. They are specifically characterizing mutants that can inhibit VEGF receptors and do not activate PDGF receptors.


  • Competitor of bevacizumab and other VEGF inhibitors
    • Wide variety of cancers
    • Macular degeneration

Key Advantages

  • Inhibits VEGF receptors to prevent angiogenesis
  • Overcomes poor efficacy of existing VEGF inhibitors
    • PDGF-B contributes significantly to VEGFR2 occupancy
    • Mutant PDGF-B outcompetes for VEGFR2 binding

Patents: Pending

Related Web Links: Imoukhuede Profile & Lab




Hardin, Clyde "Frank"

Create a Collection